Terms: = Leukemia AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
128 results:
1. Dachshund Homolog 1: Unveiling Its Potential Role in Megakaryopoiesis and
Lin GL; Chang HH; Lin WT; Liou YS; Lai YL; Hsieh MH; Chen PK; Liao CY; Tsai CC; Wang TF; Chu SC; Kau JH; Huang HH; Hsu HL; Sun DS
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542074
[TBL] [Abstract] [Full Text] [Related]
2. The effect of STAT1, miR-99b, and map2k1 in alcoholic liver disease (ALD) mouse model and hepatocyte.
Du H; Yu H; Zhou M; Hui Q; Hou Y; Jiang Y
Aging (Albany NY); 2024 Feb; 16(5):4224-4235. PubMed ID: 38431286
[TBL] [Abstract] [Full Text] [Related]
3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
4. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
5. The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas.
Salaverria I; Weigert O; Quintanilla-Martinez L
Blood Adv; 2023 Sep; 7(18):5258-5271. PubMed ID: 37561599
[TBL] [Abstract] [Full Text] [Related]
6. The cardiac glycoside ZINC253504760 induces parthanatos-type cell death and G2/M arrest via downregulation of mek1/2 phosphorylation in leukemia cells.
Zhou M; Boulos JC; Klauck SM; Efferth T
Cell Biol Toxicol; 2023 Dec; 39(6):2971-2997. PubMed ID: 37322258
[TBL] [Abstract] [Full Text] [Related]
7. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.
Roskoski R
Pharmacol Res; 2023 Jan; 187():106552. PubMed ID: 36403719
[TBL] [Abstract] [Full Text] [Related]
8. Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors.
Lebedev TD; Khabusheva ER; Mareeva SR; Ivanenko KA; Morozov AV; Spirin PV; Rubtsov PM; Snezhkina AV; Kudryavtseva AV; Sorokin MI; Buzdin AA; Prassolov VS
J Biol Chem; 2022 Aug; 298(8):102226. PubMed ID: 35787369
[TBL] [Abstract] [Full Text] [Related]
9. TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
Pérez-Carretero C; Hernández-Sánchez M; González T; Quijada-Álamo M; Martín-Izquierdo M; Santos-Mínguez S; Miguel-García C; Vidal MJ; García-De-Coca A; Galende J; Pardal E; Aguilar C; Vargas-Pabón M; Dávila J; Gascón-Y-Marín I; Hernández-Rivas JÁ; Benito R; Hernández-Rivas JM; Rodríguez-Vicente AE
Am J Hematol; 2022 Jul; 97(7):903-914. PubMed ID: 35472012
[TBL] [Abstract] [Full Text] [Related]
10. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.
Menne T; Slade D; Savage J; Johnson S; Irving J; Kearns P; Plummer R; Shenton G; Veal GJ; Vormoor B; Vormoor J; Billingham L
BMJ Open; 2022 Mar; 12(3):e059872. PubMed ID: 35246426
[TBL] [Abstract] [Full Text] [Related]
11. Advances in the treatment of Hairy Cell leukemia Variant.
Tran J; Gaulin C; Tallman MS
Curr Treat Options Oncol; 2022 Jan; 23(1):99-116. PubMed ID: 35178674
[TBL] [Abstract] [Full Text] [Related]
12. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
Roskoski R
Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
[TBL] [Abstract] [Full Text] [Related]
13. A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.
Cheng F; Yu F; Wang X; Huang K; Lu H; Wang Z
Int J Surg Pathol; 2021 Dec; 29(8):906-914. PubMed ID: 33939500
[TBL] [Abstract] [Full Text] [Related]
14. Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?
Matutes E
Expert Rev Hematol; 2021 Apr; 14(4):355-363. PubMed ID: 33759673
[TBL] [Abstract] [Full Text] [Related]
15. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Murali I; Kasar S; Naeem A; Tyekucheva S; Khalsa JK; Thrash EM; Itchaki G; Livitz D; Leshchiner I; Dong S; Fernandes SM; Getz G; Johnson A; Brown JR
Blood; 2021 Jul; 138(1):44-56. PubMed ID: 33684943
[TBL] [Abstract] [Full Text] [Related]
16. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract] [Full Text] [Related]
17. Mitogen-activated protein kinases are involved in cucurbitacin D-induced antitumor effects on adult T-cell leukemia cells.
Wang D; Shen M; Kitamura N; Sennari Y; Morita K; Tsukada J; Kanazawa T; Yoshida Y
Invest New Drugs; 2021 Feb; 39(1):122-130. PubMed ID: 32914311
[TBL] [Abstract] [Full Text] [Related]
18. Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.
Yoshino S; Yokoyama T; Sunami Y; Takahara T; Nakamura A; Yamazaki Y; Tsutsumi S; Aburatani H; Nakamura T
Blood; 2021 Jan; 137(1):75-88. PubMed ID: 32730594
[TBL] [Abstract] [Full Text] [Related]
19. Role of growth hormone signaling pathways in the development of atherosclerosis.
Ishikawa M; Toyomura J; Yagi T; Kuboki K; Morita T; Sugihara H; Hirose T; Minami S; Yoshino G
Growth Horm IGF Res; 2020; 53-54():101334. PubMed ID: 32721858
[TBL] [Abstract] [Full Text] [Related]
20. p19
Kuang Y; Han X; Cao P; Xiong D; Peng Y; Liu Z; Xu Z; Liang L; Roy M; Liu J; Nie L; Zhang J
Blood Cells Mol Dis; 2020 Nov; 85():102477. PubMed ID: 32711219
[TBL] [Abstract] [Full Text] [Related]
[Next]
